The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
In Vitro and In Vivo Activities of Synthetic Trioxolanes against Major Human Schistosome Species
Open accessAbstract
Schistosomiasis is a parasitic disease that remains of considerable public health significance in tropical and subtropical environments. Since the mainstay of schistosomiasis control is chemotherapy with a single drug, praziquantel, drug resistance is a concern. Here, we present new data on the antischistosomal properties of representative synthetic 1,2,4-trioxolanes (OZs). Exposure of adult Schistosoma mansoni for 24 h to a medium containing 20 μg/ml OZ209 reduced worm motor activity, induced tegumental alterations, and killed worms within 72 h. While exposure of S. mansoni to OZ78 had no apparent effect, addition of hemin reduced worm motor activity and caused tegumental damage. Administration of single 200-mg/kg of body weight oral doses of OZ78, OZ209, and OZ288 to mice harboring a juvenile S. mansoni infection resulted in worm burden reductions of 82.0 to 95.4%. In the adult infection model in mice, single 400-mg/kg doses of these compounds resulted in a maximum total worm burden reduction of 52.2%. High worm burden reductions (71.7 to 86.5%) were observed after administration of single 200-mg/kg doses of OZ78 and OZ288 to hamsters infected with either juvenile or adult S. mansoni . A single 200-mg/kg dose of OZ78 to hamsters infected with adult Schistosoma japonicum resulted in total and female worm burden reductions of 94.2 to 100%. Our results, along with the low toxicity, metabolic stability, and good pharmacokinetic properties of the OZs, indicate the potential for the development of novel broad-spectrum antischistosomal OZ drug candidates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630
Haynes, R. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776743129 · Cited by 224 · cited 1×
“The semisynthetic artemisinin derivatives (e.g., artemether and artesunate) are currently the most potent antimalarial drugs available and are being used on a very large scale, particularly in combination with other antimalarials (1, 11 ).”
Background
Cited by
Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis
Doenhoff, M. J., Cioli, D., & Utzinger, J. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328318978f · Cited by 806
Self-citationCrespo-Ortiz, M. P., & Wei, M. Q. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/247597 · Cited by 382
Chemotherapy of schistosomiasis: present and future
Caffrey, C. R. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.05.031 · Cited by 277
Metadata
- Authors
- Xiao, S.-H., Keiser, J., Chollet, J., Utzinger, J., Dong, Y., Endriss, Y., Vennerstrom, J. L., & Tanner, M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2007-04
- Volume
- 51
- Issue
- 4
- Pages
- 1440-1445
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2126906819
- Cited by
- 184
- References
- 2
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In Vitro and In Vivo Activities of Synthetic Trioxolanes against Major Human Schistosome Species. https://app.cochat.ai/papers/10.1128/aac.01537-06
- The paper
- Xiao, S.-H., Keiser, J., Chollet, J., Utzinger, J., Dong, Y., Endriss, Y., Vennerstrom, J. L., & Tanner, M. (2007). In Vitro and In Vivo Activities of Synthetic Trioxolanes against Major Human Schistosome Species. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01537-06
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.